Citations

Showing 10 of 108081 citations.

Pooled analysis of three randomized, double‐blind, placebo controlled trials with rimonabant for smoking cessation
Robinson, Jason D. , Aubin, Henri‐Jean , Dale, Lowell C., Niaura, Raymond , Anthenelli, Robert M. , Group, the STRATUS, Cinciripini, Paul M , Karam‐Hage, Maher , Group, the STRATUS

Mayo Clinic

Addiction Biology | April 21, 2017 | Volume: 23 | Issue: 1 | Pages: 291-303

10.1111/adb.12508 | PMID 28429843 Get It

AbstractDespite the withdrawal of CB1 antagonists, such as rimonabant, from the market and from active clinical development because of concerns about their side effect profiles, research suggests that the endocannabinoid system may play an important role in modulating nicotine's effects. We report the combined results, using a pooled analysis, of three previously unpublished trials assessing rimonabant as a smoking cessation pharmacotherapy conducted between 2002 and 2004. Smokers (n = 2097) motivated to quit were enrolled in three randomized, double‐blind, placebo‐controlled trials, STRATUS EU, US, and META, which consisted of a 10‐week treatment period with either rimonabant 20 mg (n = 789), 5 mg (n = 518; used in only two of the three studies), or placebo (n = 790), in conjunction with brief counseling. The impact of drug on prolonged abstinence and adverse events was examined at 8 weeks (end‐of‐treatment) and at 48 weeks (available for STRATUS EU and US) after the targeted quit date. Rimonabant 20 mg resulted in significantly higher abstinence at end‐of‐treatment and at 48 weeks post‐targeted quit date compared with placebo, while rimonabant 5 mg and placebo did not differ. Serious AEs did not differ by drug group. The 20 mg rimonabant dose, compared with placebo, produced increased nausea, diarrhea, anxiety symptoms, hyporexia, and vomiting, and decreased headache, constipation, and cough. These results support rimonabant 20 mg as a modestly effective aid for smoking cessation. Although work on CB1 antagonists such as rimonabant has mostly been stopped because of unacceptable adverse events, these results may inform and spur the development of other endocannabinoids for smoking cessation.
Intertrochanteric Osteotomy for Femoral Neck Nonunion: Does “Undercorrection” Result in an Acceptable Rate of Femoral Neck Union?
Shearer, David , Barei, David P. , Nork, Sean E., Yuan, Brandon J.

Mayo Clinic

Journal of Orthopaedic Trauma | April 21, 2017 | Volume: 31 | Issue: 8 | Pages: 420-426

10.1097/bot.0000000000000869 | PMID 28430719 Get It

Objectives: To analyze the radiographic outcomes of intertrochanteric osteotomy for the treatment of femoral neck nonunion with “undercorrection” of the Pauwels angle and relative preservation of the proximal femoral anatomy. Design: Retrospective cohort study. Setting: Level-1 trauma center. Patients: Thirty-two patients with established femoral neck nonunions that had been treated with intertrochanteric osteotomy were retrospectively identified through Current Procedural Terminology codes. Seven patients were treated with 30 degree closing wedge osteotomy and 25 with a 20 degree or smaller osteotomy. Intervention: Valgus-producing intertrochanteric osteotomy with a blade plate. Main Outcome Measurements: Femoral neck and intertrochanteric osteotomy osseous union. Results: Thirty-one of 32 patients (97%) went on to osseous union of the femoral neck and all intertrochanteric osteotomies healed. There was no significant difference in the rate of union of the femoral neck between those patients treated with 30 versus 20 degree or less osteotomies. After osteotomy, the mean Pauwels angle decreased from 71 degrees (range 52–95 degrees) to 47 degrees (range 23–67 degrees) and the mean proximal femoral offset decreased by 11 mm (range 0–23 mm). Seven patients developed radiographic signs of avascular necrosis after osteotomy (22%). Three patients of these patients were converted to total hip arthroplasty (9%). Patients treated with a 30 degree osteotomy were more likely to develop avascular necrosis (67% vs. 12%, P-value = 0.014). Conclusions: Valgus-producing intertrochanteric osteotomy with a smaller degree of correction than has been traditionally described leads to an excellent rate of radiographic union while preserving more of the native proximal femoral anatomy. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Regulation of vascular large-conductance calcium-activated potassium channels by Nrf2 signalling
Wang, Xiao-Li, Sun, Xiaojing , Chai, Qiang , Thompson, Benjamin , Shen, Win-Kuang, Lü, Tong , Lee, Hon-Chi, Li, Jingchao, Li, Yong , Wang, Xiao-Li, Li, Jingchao , Lu, Tong

Mayo Clinic

Diabetes and Vascular Disease Research | April 21, 2017 | Volume: 14 | Issue: 4 | Pages: 353-362

10.1177/1479164117703903 | PMID 28429615 Get It

BK channels are major ionic determinants of vasodilation. BK channel function is impaired in diabetic vessels due to accelerated proteolysis of its beta-1 (BK-β1) subunits in response to increased oxidative stress. The nuclear factor E2-related factor-2 (Nrf2) signalling pathway has emerged as a master regulator of cellular redox status, and we hypothesized that it plays a central role in regulating BK channel function in diabetic vessels. We found that Nrf2 expression was markedly reduced in db/db diabetic mouse aortas, and this was associated with significant downregulation of BK-β1. In addition, the muscle ring finger protein 1 (MuRF1), a known E-3 ligase targeting BK-β1 ubiquitination and proteasomal degradation, was significantly augmented. These findings were reproduced by knockdown of Nrf2 by siRNA in cultured human coronary artery smooth muscle cells. In contrast, adenoviral transfer of Nrf2 gene in these cells downregulated MuRF1 and upregulated BK-β1 expression. Activation of Nrf2 by dimethyl fumarate preserved BK-β1 expression and protected BK channel and vascular function in db/db coronary arteries. These results indicate that expression of BK-β1 is closely regulated by Nrf2 and vascular BK channel function can be restored by Nrf2 activation. Nrf2 should be considered a novel therapeutic target in the treatment of diabetic vasculopathy.
Automated T‐wave analysis can differentiate acquired QT prolongation from congenital long QT syndrome
Sugrue, Alan , Křemen, Václav , Bos, J. Martijn , Qiang, Bo , Rohatgi, Ram K., Sapir, Yehu , Brady, Peter A. , Asirvatham, Samuel J. , Friedman, Paul A. , Ackerman, Michael J. , Caraballo, Pedro J. , Noseworthy, Peter A. , Attia, Zachi I. , Asirvatham, Samuel J , Kremen, Vaclav , Bos, Johan M

Mayo Clinic

Annals of Noninvasive Electrocardiology | April 21, 2017 | Volume: 22 | Issue: 6 | Pages: No page available

10.1111/anec.12455 | PMID 28429460 Get It

BackgroundProlongation of the QT on the surface electrocardiogram can be due to either genetic or acquired causes. Distinguishing congenital long QT syndrome (LQTS) from acquired QT prolongation has important prognostic and management implications. We aimed to investigate if quantitative T‐wave analysis could provide a tool for the physician to differentiate between congenital and acquired QT prolongation.MethodsPatients were identified through an institution‐wide computer‐based QT screening system which alerts the physician if the QTc ≥ 500 ms. ECGs were retrospectively analyzed with an automated T‐wave analysis program. Congenital LQTS was compared in a 1:3 ratio to those with an identified acquired etiology for QT prolongation (electrolyte abnormality and/or prescription of known QT prolongation medications). Linear discriminant analysis was performed using 10‐fold cross‐validation to statistically test the selected features.ResultsThe 12‐lead ECG of 38 patients with congenital LQTS and 114 patients with drug‐induced and/or electrolyte‐mediated QT prolongation were analyzed. In lead V5, patients with acquired QT prolongation had a shallower T wave right slope (−2,322 vs. −3,593 mV/s), greater T‐peak‐Tend interval (109 vs. 92 ms), and smaller T wave center of gravity on the x axis (290 ms vs. 310 ms; p < .001). These features could distinguish congenital from acquired causes in 77% of cases (sensitivity 90%, specificity 58%).ConclusionT‐wave morphological analysis on lead V5 of the surface ECG could successfully differentiate congenital from acquired causes of QT prolongation.
Consensus Statement on Inpatient Use of Continuous Glucose Monitoring
Wallia, Amisha , Rushakoff, Robert J , Klonoff, David C. , Rubin, Daniel J. , Thompson, Bithika , Cook, Curtiss B. , Umpierrez, Guillermo E. , Golden, Sherita Hill

Mayo Clinic

Journal of Diabetes Science and Technology | April 21, 2017 | Volume: 11 | Issue: 5 | Pages: 1036-1044

10.1177/1932296817706151 | PMID 28429611 Get It

In June 2016, Diabetes Technology Society convened a panel of US experts in inpatient diabetes management to discuss the current and potential role of continuous glucose monitoring (CGM) in the hospital. This discussion combined with a literature review was a follow-up to a meeting, which took place in May 2015. The panel reviewed evidence on use of CGM in 3 potential inpatient scenarios: (1) the intensive care unit (ICU), (2) non-ICU, and (3) transitioning outpatient CGM use into the hospital setting. Panel members agreed that data from limited studies and theoretical considerations suggested that use of CGM in the hospital had the potential to improve patient clinical outcomes, and in particular reduction of hypoglycemia. Panel members discussed barriers to widespread adoption of CGM, which patients would benefit most from use of this technology, and what type of outcome studies are needed to guide use of CGM in the inpatient setting.
Perioperative Outcomes of Robotic-Assisted Hysterectomy Compared With Open Hysterectomy
Gali, Bhargavi , Plevak, David J., Schroeder, Darrell R. , Wilson, Timothy O., Jankowski, Christopher J., Schroeder, Darrell, Bakkum‐Gamez, Jamie N. , Schroeder, Darrell

Mayo Clinic

Anesthesia & Analgesia | April 21, 2017 | Volume: 126 | Issue: 1 | Pages: 127-133

10.1213/ane.0000000000001935 | PMID 28430689 Get It

BACKGROUND: Increasing numbers of robotic hysterectomies (RH) are being performed. To provide ventilation (with pneumoperitoneum and steep Trendelenburg position) for these procedures, utilization of lung protective strategies with limiting airway pressures and tidal volumes is difficult. Little is known about the effects of intraoperative mechanical ventilation and high peak airway pressures on perioperative complications. We performed a retrospective review to determine whether patients undergoing RH had increased pulmonary complications compared to total abdominal hysterectomy (TAH). METHODS: We performed a single center retrospective review comparing the intraoperative, anesthetic, and immediate and 30-day postoperative course of patients undergoing RH to TAH, including intraoperative ventilatory parameters and respiratory complications. Patients undergoing TAH (201) from 2004 to 2006 were compared to RH (251) from 2009 to 2012. It was our hypothesis that patients undergoing RH would have increased incidence of postoperative pulmonary complications. A secondary hypothesis was that morbid obesity predicts pulmonary complications in patients undergoing RH. Complications were compared between groups using Fisher’s exact test. To account for potential confounders, the primary analysis was performed for a subgroup of patients matched on the propensity for RH. RESULTS: A total of 351 RH and 201 TAH procedures are included. Higher inspiratory pressures were required in ventilation of the RH group (median [25th, 75th] 31 [26, 36] cm H 2 O) than the TAH group (23 [19, 27] cm H 2 O) ( P < .001) at 30 minutes after incision. Peak inspiratory pressures at 30 minutes after incision for RH increased according to increasing body mass index group ( P < .001). There were 163 RH and 163 TAH procedures included in the propensity matched analysis. From this analysis, there were no significant differences in cardiopulmonary complications between RH and TAH (0.6% vs 1.2%; odds ratio = 2.0, 95% confidence interval = 0.2–2.4; P = 1.00). Surgical site infection was significantly lower in the RH compared to TAH group (0.6% vs 8.6%; P < .001). Hospital length of stay was longer for those who underwent TAH versus RH (median [25th, 75th] 2 [2, 3] vs 1 [0, 2] days; P < .001). CONCLUSIONS: There was no significant difference in perioperative complications in obese and morbidly obese women compared to nonobese undergoing RH. Patients undergoing RH had shorter hospital stays, fewer infectious complications, and no increase in overall complications compared to TAH. Higher ventilatory airway pressures (RH versus TAH and obese versus nonobese) did not result in an increase in cardiopulmonary or overall complications. We believe that peritoneal insufflation attenuates the effect of high airway pressures by raising intrapleural pressure and reducing the gradient across terminal bronchioles and alveoli. Thus, we propose that lung protective strategies for patients undergoing RH account for the markedly elevated intraperitoneal and intrapleural pressures, whereas transpulmonary airway pressures remain static. This reduced transpulmonary gradient attenuates the strain on lung tissue that would otherwise be imposed by ventilation at high pressures.
Acute on chronic liver failure
Kamath, Patrick S.

Mayo Clinic

Clinical Liver Disease | April 21, 2017 | Volume: 9 | Issue: 4 | Pages: 86-88

10.1002/cld.625 | PMID 30992966 Get It

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Auclair, Daniel , Kelloff, Gary J. , Sigman, Caroline C. , Avet‐Loiseau, Hervé , Farrell, Ann T. , Gormley, Nicole , Kumar, Shaji , Munshi, Nikhil C. , Cavo, Michèle , Davies, Faith E. , Bacco, Alessandra Di , Dickey, Jennifer S., Gutman, Steven, Higley, Howard R., Hussein, Mohamad A., Jessup, J. Milburn , Little, Richard F. , Loberg, Robert D., Lohr, Jens G. , Mukundan, Lata , Omel, James, Pugh, Trevor J. , Reaman, Gregory H. , Robbins, Michael , Sasser, A. Kate, Valente, Nancy, Zamagni, Elena , Anderson, Kenneth C. , Landgren, Ola , Kirsch, Ilan R. , Pugh, Trevor J , Davies, Faith E , Gormley, Nicole , Zamagni, Elena

Mayo Clinic

Clinical Cancer Research | April 20, 2017 | Volume: 23 | Issue: 15 | Pages: 3980-3993

10.1158/1078-0432.ccr-16-2895 | PMID 28428191 Get It

Abstract Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new sensitive and specific tools for disease prognostication and management. Assessment of minimal residual disease (MRD) in response to therapy is one of these tools, as longer progression-free survival (PFS) is seen consistently among patients who have achieved MRD negativity. Current therapies lead to unprecedented frequency and depth of response, and next-generation flow and sequencing methods to measure MRD in bone marrow are in use and being developed with sensitivities in the range of 10−5 to 10−6 cells. These technologies may be combined with functional imaging to detect MRD outside of bone marrow. Moreover, immune profiling methods are being developed to better understand the immune environment in myeloma and response to immunomodulatory agents while methods for molecular profiling of myeloma cells and circulating DNA in blood are also emerging. With the continued development and standardization of these methodologies, MRD has high potential for use in gaining new drug approvals in myeloma. The FDA has outlined two pathways by which MRD could be qualified as a surrogate endpoint for clinical studies directed at obtaining accelerated approval for new myeloma drugs. Most importantly, better understanding of MRD should also contribute to better treatment monitoring. Potentially, MRD status could be used as a prognostic factor for making treatment decisions and for informing timing of therapeutic interventions. Clin Cancer Res; 23(15); 3980–93. ©2017 AACR.
In Reply
Apple, Fred S. , Sandoval, Yader , Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | April 20, 2017 | Volume: 63 | Issue: 6 | Pages: 1167-1170

10.1373/clinchem.2017.273250 | PMID 28428359 Get It

Effect of Repeat Measurements of High-Sensitivity Cardiac Troponin on the Same Sample Using the European Society of Cardiology 0-Hour/1-Hour or 2-Hour Algorithms for Early Rule-Out and Rule-In for Myocardial Infarction
Kavsak, Peter A. , Clark, Lorna , Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | April 20, 2017 | Volume: 63 | Issue: 6 | Pages: 1163-1165

10.1373/clinchem.2017.272914 | PMID 28428358 Get It